ELEKTA AB/ADR (OTCMKTS:EKTAY) Upgraded at Morgan Stanley
Morgan Stanley upgraded shares of ELEKTA AB/ADR (OTCMKTS:EKTAY) from an underweight rating to an equal weight rating in a research report report published on Wednesday morning, The Fly reports.
Several other brokerages have also recently issued reports on EKTAY. UBS Group cut shares of ELEKTA AB/ADR from a buy rating to a neutral rating in a report on Thursday, May 7th. Zacks Investment Research upgraded shares of ELEKTA AB/ADR from a sell rating to a hold rating in a research note on Wednesday, June 24th. Finally, JPMorgan Chase & Co. reiterated an underweight rating on shares of ELEKTA AB/ADR in a research note on Monday, June 1st. Two analysts have rated the stock with a sell rating and four have issued a hold rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $9.50.
Shares of ELEKTA AB/ADR stock opened at $10.11 on Wednesday. The company has a fifty day simple moving average of $9.40 and a 200-day simple moving average of $9.79. ELEKTA AB/ADR has a 12-month low of $6.25 and a 12-month high of $14.76. The company has a current ratio of 1.00, a quick ratio of 0.76 and a debt-to-equity ratio of 0.45. The stock has a market cap of $3.86 billion, a price-to-earnings ratio of 29.74 and a beta of 0.70.
About ELEKTA AB/ADR
Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT.
Receive News & Ratings for ELEKTA AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA AB/ADR and related companies with MarketBeat.com's FREE daily email newsletter.